Citation Impact
Citing Papers
Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function
2012
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
T Regulatory Cells Support Plasma Cell Populations in the Bone Marrow
2017 StandoutNobel
Therapeutic HER2/Neu DNA Vaccine Inhibits Mouse Tumor Naturally Overexpressing Endogenous Neu
2004
Differential Cytokine and Chemokine Gene Expression by Human NK Cells Following Activation with IL-18 or IL-15 in Combination with IL-12: Implications for the Innate Immune Response
1999
The biology of human natural killer-cell subsets
2001 Standout
Evidence-Based Protocol for Diabetic Foot Ulcers
2006
IL-15: targeting CD8+T cells for immunotherapy
2005
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
2006 Standout
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
1999 Standout
Wound healing and its impairment in the diabetic foot
2005 Standout
Work-up of the diabetic foot
2002
Magnetic Resonance Imaging for Diagnosing Foot Osteomyelitis
2007
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
2007 Standout
Depression Is a Risk Factor for Noncompliance With Medical Treatment
2000 Standout
Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy
2000
Protocol for treatment of diabetic foot ulcers
2004
An evidence-based approach to diabetic foot infections
2003
Immune reconstitution
2002 StandoutNobel
Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines.
1996
Imaging modalities of the diabetic foot
2003
Diagnostic Performance of FDG-PET, MRI, and Plain Film Radiography (PFR) for the Diagnosis of Osteomyelitis in the Diabetic Foot
2009
Ontogeny and Expansion of Human Natural Killer Cells: Clinical Implications
2001
Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances
2008 Standout
CD4 cell and CD8 cell-mediated resistance to HIV-1 infection in exposed uninfected intravascular drug users in Vietnam
2003 StandoutNobel
MR Imaging of the Diabetic Foot: Diagnostic Challenges
2005
Patient Adherence and Medical Treatment Outcomes
2002 Standout
Diabetic foot ulcers
2003 Standout
Diabetic Foot Disorders: A Clinical Practice Guideline (2006 Revision)
2006 Standout
Interleukin-2 and interleukin-15: immunotherapy for cancer
2002
Periventricular Hemorrhagic Infarction: Risk Factors and Neonatal Outcome
2006
β-Lactams and β-Lactamase Inhibitors: An Overview
2016 Standout
TREG-cell therapies for autoimmune rheumatic diseases
2014 StandoutNobel
The diabetic foot.
2000
Opportunities for Treg cell therapy for the treatment of human disease
2023 StandoutNobel
Genetic dissection of innate immunity to infection: the mouse cytomegalovirus model
2004 StandoutNobel
Pedal Abscesses in Patients Suspected of Having Pedal Osteomyelitis: Analysis with MR Imaging
2002
The Optimized Evaluation of Diabetic Foot Infection by Dual Isotope SPECT/CT Imaging Protocol
2010
Diabetic foot osteomyelitis
2008
Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant
2009 StandoutNobel
Natural Killer Cells from HIV-1+ Patients Produce C-C Chemokines and Inhibit HIV-1 Infection
1998
Charcot neuroarthropathy in diabetes mellitus
2002
Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420
1999
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages
1999 StandoutNobel
Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.
1996
Interleukin-5–producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy
2014
Augmented IL-15Rα Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice
2012 StandoutNobel
The Use and Misuse of New Antibiotics
1995
In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338
1989
Interleukin 15: biology and relevance to human disease
2001
In vitro activity and beta-lactamase stability of LJC 10,627
1992
Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells
2002 StandoutNobel
Current Topics Review: Charcot Neuroarthropathy of the Foot and Ankle
2005
Preoperative Imaging of Charcot Neuroarthropathy in Diabetic Patients: Comparison of Ring PET, Hybrid PET, and Magnetic Resonance Imaging
2004
Chemokine immunobiology in HIV-1 pathogenesis
1999
Diagnosis and Treatment of Diabetic Foot Infections
2004
2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infectionsa
2012 Standout
Patent Ductus Arteriosus in the Neonate
1986
Cellular and molecular basis of wound healing in diabetes
2007 Standout
Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2
2001 StandoutNobel
IL-15: targeting CD8+ T cells for immunotherapy
2005
NATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate Cytokines
1999 Standout
Works of Brian Lipman being referenced
Imipenem: A New Carbapenem Antibiotic
1988
Detection of Osteomyelitis in the Neuropathic Foot: Nuclear Medicine, MRI, and Conventional Radiography
1998
Abnormal Cerebral Hemodynamics in Preterm Infants with Patent Ductus Arteriosus
1982
Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity
1995